-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine (NE) cancer that accounts for approximately 15% of all lung cancer types.
In the United States alone, the annual incidence of the disease exceeds 34,000
.
The standard of treatment for SCLC includes platinum and etoposide (etoposide) chemotherapy strategies.
Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine (NE) cancer, which accounts for about 15% of all lung cancer types.
SCLC is characterized by functional p53 and RB12 loss mutants and high tumor burden (TMB), which also indicates that the tumor may have immune immunogenic and an immune checkpoint block (the ICB) responsive to therapy
.
However, previous studies have shown that immune checkpoint blockade (ICB) only benefits a small number of SCLC patients, and its underlying mechanism is not clear
.
.
Immune checkpoint blockade (ICB) benefits only a small proportion of SCLC patients, and its underlying mechanism is not clear
Result analysis of recurrent small cell lung cancer discovery cohort
Result analysis of recurrent small cell lung cancer discovery cohortTo determine the relevant predictors of ICB clinical benefit, the researchers performed immunogenomics analysis on tumor samples from patients with recurrent SCLC
.
The results showed that the tumor tissues of patients who benefited from ICB therapy showed cytotoxic T cell infiltration, high expression levels of APM (antigen processing and presentation mechanism) genes, and low neuroendocrine (NE) differentiation
The tumor tissues of patients who benefited from ICB therapy showed cytotoxic T cell infiltration, high expression levels of APM (antigen processing and presentation mechanism) genes, and low neuroendocrine (NE) differentiation
The level of Notch signaling pathway is related to the clinical benefit of immune checkpoint blockade
The level of Notch signaling pathway is related to the clinical benefit of immune checkpoint blockadeFurther studies have shown that the increase of Notch signal is positively correlated with lower NE differentiation status, and this factor can most significantly predict the clinical benefit of ICB treatment
.
Activation of Notch signaling in human NE SCLC cell lines induces a low NE differentiation phenotype, which is marked by increased APM gene expression, which also indicates the activation of Notch signaling, low NE differentiation status, and increased tumor intrinsic There is a certain correlation between immunity
The increase of Notch signal is positively correlated with lower NE differentiation status, and this factor can most significantly predict the clinical benefit of ICB treatment
Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer.
Leave a message here